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US census divisions: Mid-West, West, North-East and South. Data were 
abstracted from 2009; the latest year that US Census data, HIRD and MarketScan 
data were available. Patients were required to have generated at least 1 health 
care claim to be included in the analysis. RESULTS: The HIRD (n=14,794,609) and 
MarketScan (n=42,632,943) databases showed remarkable agreement between 
gender and age groups for all four geographic regions. Both MarketScan and the 
HIRD databases over represented US Census data for the age groups below 5 
years and above 30 years of age. These agreement levels were consistent across 
all four regions and two gender groups. There was close agreement from ages 5 
to 30 years for all sources. HIRD and MarketScan data under-represented the US 
Census data for age groups above age 65 years. CONCLUSIONS: The employment 
characteristic is present in both the HIRD and MarketScan databases, and can be 
quantified against the US Census. HIRD and MarketScan data are equally 
affected by the commercial database employment characteristic. The HIRD and 
MarketScan data agreement indicate that for research on specific disease or drug 
classification, it would be possible to extrapolate weighting data against US 
Census data to yield accurate estimates of disease prevalence among patients, or 
claims for coexisting and comorbid conditions and pharmacy claims.  
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NOVEL NATURAL LANGUAGE PROCESSING ALGORITHM CAN ASCERTAIN 
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OBJECTIVES: Joint replacement is one of the commonest elective procedure 
performed in the elderly veterans. Database studies assume the occurrence of 
revision to be the same side as the most recent primary, in the absence of 
laterality being captures in claims databases. A recent Medicare study found that 
such an assumption had a significant error rate with only 71% revision on the 
same side as the most recent joint replacement. METHODS: We utilized the 
Veterans Affairs (VA) administrative and clinical databases from fiscal years 2002 
to 2010. We defined the joint replacement cohort based on the presence of 
Common Procedure Terminology (CPT) codes for total knee, hip or shoulder joint 
arthroplasty (TKA, THA, TSA). We used NLP ascertainment of laterality of 
primary and revision joint replacement. RESULTS: The cohorts consisted of 
84,495 patients with 87,495 procedures. Mean age was 63 years, 94% were male; 
84% were Caucasian, 14% were African-American and 2% were other. 73,488 had 
operative notes available and constituted our analytic dataset. Joint laterality 
was established based on text data for >98% of primary and >97% of all joint 
replacement cohorts. We found that 57% of the primary TKA were right, 41% 
were left and 1% simultaneous bilateral. Similar proportions were noted for 
primary THA and primary TSA. For revision TKA, THA and TSA, similar 
proportions were noted. CONCLUSIONS: NLP can obtain the laterality of joint 
replacement surgery and this can assist in improving the quality of database 
studies of joint replacement surgery that use the VA databases.  
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ESTABLISHING A WEIGHTING METHODOLOGY TO COMPUTE THE NUMBER OF 
PATIENTS WITH DISEASE USING CLAIMS DATA AND CENSUS POPULATION IN 
THE UNITED STATES  
Wasser T1, Wu B1, Ycas J2, Tunceli O1, Cziraky MJ1 
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OBJECTIVES: Commercial claims databases are thought to over-represent 
working age groups and under-represent older age groups because of 
employment bias attributable to their population of working age individuals, and 
their dependents, who have employer based insurance coverage. METHODS: 
Four disease classifications (acute coronary syndromes, dyslipidemia, breast 
cancer, and major depressive disorder[MDD]), and four drugs classes (statins, 
anti-platelets, anti-estrogens and atypical antipsychotics) were used to develop 
and evaluate linear weighting methods compared to the United States (US) 
Census data. Any patient within the HealthCore Integrated Research Database 
(HIRD) with a claim for any of the disease or drug classifications during 2009 was 
eligible for this analysis. This year was selected because it was the latest year for 
which US Census data were available. Linear weighting method was used as the 
‘Weight = Estimated Population Value from the US Census/HIRD value. RESULTS: 
A total of 14,794,609 patients in the HIRD met the inclusion criteria. Weights 
were calculated for the Mid-West, West, North-East and South geographic 
regions, and were stratified by gender and age using US Census age groups. For 
example, for 1,227 North-East-based male patients, aged 15-19 years, in the HIRD 
database who were diagnosed with an MDD the weight derived from US Census 
data was 1.10, indicating that an estimated 1,353 patients in the North-East 
region with MDD. CONCLUSIONS: The number of individuals in the US 
population with any one of four disease or drug classifications can be safely 
estimated using a linear weighting methodology, which makes it possible to 
calculate estimates of the total number of patients in the US population, or by 
geographic region, and further stratified by age group and gender. Such 
estimation is useful for research requiring estimation numbers of patients with a 
disease condition or pharmacy utilization.  
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USA  
OBJECTIVES: Substantial evidence suggests that following an enhanced recovery 
after surgery (ERAS) program is effective in improving post-surgical outcomes. To 
examine the potential associations between compliance with ERAS protocol 
elements and post-op fluid use, opioid use, hospital length of stay (LOS), hospital 
costs, and readmissions, would require combining data elements from the ERAS 
program with regularly collected retrospective data elements in a large multi-
hospital database. The objective of this study was to combine information from a 
prospective dataset with a matched retrospective data source. METHODS: Duke 
University Medical Center (DUMC) collected data on colorectal surgery patients 
in order to determine eligibility for inclusion in the study. With IRB approval, we 
matched selected patients in the Premier research database on criteria of age, 
gender, discharge date, procedure date, length of stay, presence of a colorectal 
procedure during stay, and presence of a colorectal procedure. All matches were 
verified by physicians at DUMC. RESULTS: Of the 240 patients in the DUMC 
database, 206 (85.8%) matched on all variables. One other patient matched, 
except on having a colorectal procedure on an identical date. Thirteen (5.4%) 
were a match, except on length of stay. Expanding the age criteria to ±1 year, we 
were able to match 7 (2.9%) additional patients. Similarly, allowing the procedure 
date to match within ±1 day increased the total by one more patient. Eight (3.3%) 
patients required a manual match by discharge date and presence of a colorectal 
procedure during the hospital stay. The final four (1.7%) patients could not be 
matched because their discharge date was outside the range of the Premier 
database. CONCLUSIONS: Using the different matching approaches criterion, we 
were able to link nearly all patients from the DUMC prospective database to the 
Premier retrospective dataset. This flexible approach can be utilized with other 
databases.  
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OBJECTIVES: To evaluate the use of the population-based Emilia-Romagna 
region (RER) administrative database for drug outcomes studies using as an 
example the previously documented increased mortality risk amongst new users 
of conventional versus atypical antipsychotic medications. METHODS: We 
conducted a new user cohort study among 23,681 Italian RER patients aged 65 or 
older who initiated treatment with a conventional or atypical antipsychotic 
between July 1, 2009 and June 30, 2011. The 180-day mortality was compared for 
patients in each treatment group using Cox proportional hazards models that 
were adjusted for mortality risk factors, including demographic and clinical 
characteristics, use of other medications, and measures of health services 
utilization intensity, all measured prior to antipsychotic initiation. We conducted 
a systematic review and meta-analysis of studies with similar methods against 
which we compared our results. RESULTS: Amongst 14,462 patients prescribed 
conventional and 9,212 prescribed atypical antipsychotics, we observed 2,402 
(16.6%) and 821(8.9%) deaths during follow-up, respectively. New users of 
conventional antipsychotics were older and generally had higher prevalences of 
outcome risk factors and higher health service use intensity at baseline. The 
crude hazard ratio (HR) was 1.95 (95% confidence interval [CI], 1.80-2.11), which 
decreased to 1.47 (95% CI, 1.35-1.60) after full adjustment. We identified seven 
published studies examining this association using similar methods. The pooled 
HR from these seven studies was 1.34 (95% CI, 1.28-1.39). Upon inclusion of our 
study, the meta-analysis yielded a summary estimate of 1.35 (95% CI, 1.31-1.40) 
without introducing any heterogeneity (I2 = 0%; p=0.455). CONCLUSIONS: Our 
results support the findings of previous studies and provide a refined estimate of 
the association between increased mortality amongst elderly patients taking 
conventional versus atypical antipsychotics. Our study provides support for the 
use of the RER database for pharmacoepidemiology studies.  
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UTILIZING PHARMACY RETAIL DATA TO MEASURE PRIMARY MEDICATION 
NON-ADHERENCE  
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West-Strum D1 
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OBJECTIVES: The purpose of the study was to calculate primary medication non-
adherence (PMN), using the Pharmacy Quality Alliance's (PQA) quality measure 
with retail pharmacy transaction data. Primary non-adherence is an instance 
whereby patients fail to initiate a pharmacotherapy regimen following a 
recommendation by a physician or other health care provider (a prescription). 
METHODS: De-identified, pharmacy transactional data for calendar years 2010 
and 2011 from 100 pharmacies of a pharmacy grocery chain were used. Primary 
medication non-adherence was defined as when a new medication was 
prescribed for a patient age 18 or older, but was not obtained from the pharmacy 
within 30 days. A set list of chronic medications was constructed that would 
warrant a patient needing to pick the medication up in a timely manner to begin 
therapy. Additionally, only electronic prescriptions were assessed as the data 
captured for prescription origination date and medication pickup date could not 
be genuinely accounted for in paper prescriptions. A prescription was 
categorized as new drug therapy if the medicine prescribed (or its generic 
equivalent) had not been filled for the patient by the pharmacy during the prior 
180 days. If the prescription was deemed to be a newly initiated drug therapy, it 
was included in the denominator for the measure. The numerator was populated 
when a newly initiated drug therapy or its therapeutic equivalent was not filled 
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within 30 days of the prescription’s origination date. RESULTS: Using the PQA-
developed PMN measure, these 100 pharmacies had an overall PMN rate of 9.3%. 
The measure could be calculated using the pharmacy transaction data; however, 
some adjustments (e.g., assumption that patient did not receive drug at another 
pharmacy) had to be made. CONCLUSIONS: Retail pharmacy data can be used to 
measure quality indicators, like PMN. These measures will have limitations, as 
do other quality indicator measures.  
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USING A CLAIMS DATA-BASED SENTINEL SYSTEM TO IDENTIFY DRUG SAFETY 
AND OUTCOMES ISSUES: METHODOLOGY AND RESULTS OF ANALYSIS ON FIVE 
MILLION LIVES  
Wei H1, Mehta R2, Steinberg G1 
1Aetna, New York, NY, USA, 2ActiveHealth Management, New York, NY, USA  
OBJECTIVES: We present the methodology for a near-real-time 
Pharmacovigilance & Drug Safety System (PDSS) to detect relationships between 
indications, drugs and outcomes. Combinations are user-selectable from a 
library of clinical scenarios including indications, agents and outcomes. 
Exemplary results for drug-outcome pairs from the PDSS are illustrated. 
METHODS: Deidentified claims data for five million individuals covering a 12-
month span was analyzed. A ‘Heat-Map’ was generated with relative risk (RR) for 
combinations of 73 DDCs and 39 HOIs. Clinical indications (on- and off-label), 
presence of drug, and outcomes were identified as, respectively,1+ ICD-9 
claim(s), 1+ NDC codes for a drug refill, and outcome code present in months 6-
12 but not in month 1-6. RR and Chi-Squared were calculated for every 
combination (SAS 9.3). RESULTS: PDSS generated 47,319 indication-drug-
outcome combinations. Run time was less than 48 hours. At a nominal threshold 
of at least 5 unique patients chi-square (X2) value of over 5, 13,094 (28%) of the 
combinations were identified for further inspection. Example results included: 
GERD-PPI-Bleeding:0.648 (x2=139); GERD-PPI-Fracture:1.42(x2=11.1); Hypertension-
ACEI-CHF:0.81(x2=19.5); Hypertension-metoprolol-Renal failure:1.78(x2=86.7); 
Non-valvular Atrial fibrillation-Dabigatran-Bleeding:1.1(x2=0.2); Valvular Atrial 
fibrillation-Dabigatran-Bleeding:1.3 (x2=2.6); mechanical heart valve-dabigatran-
stroke:8.76(x2=6.5). CONCLUSIONS: The PDSS rapidly quantifies indication-drug-
outcome combinations from real-world data. Such a system can provide 
prospective and continuous drug surveillance and comparative effectiveness & 
harms analysis. This can permit more efficient targeting of further analyses. 
Finally, the PDSS is constructed such that it is rapidly able to incorporate new 
indication, drug, and/or outcome data from claims or clinical (i.e. EMR) data sets.  
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OBJECTIVES: To examine the concordance in diabetes diagnosis between 
electronic medical records (EMR) and claims data and to explore an appropriate 
definition for diabetes in EMR data. METHODS: Retrospective study using the 
Linked Quintile EMR and MarketScan Commercial and Medicare Databases 
(MSN). Patients with at least one EMR every year and continuous enrollment in 
MSN between January 1, 2009 through December 31, 2011 were included in the 
study. Patients with at least one inpatient or two outpatient claims for diabetes 
(ICD-9-CM 250.xx) in MSN were identified as diabetic patients. Diabetes was 
defined in the EMR data using various criteria, including HbA1C≥6.5%, diabetes in 
the problem list, any insulin prescription, ≥2 oral anti-diabetic agents, and ≥2 
abnormal fasting plasma glucose tests. An extended definition of diabetes based 
on the presence of any of the criteria mentioned above was also evaluated. 
RESULTS: Among the 257,899 patients meeting the study inclusion criteria, 
34,383 were identified as diabetic patients using MSN claims. When the extended 
definition was used, 27,219 patients were defined as diabetic in EMR, an 11.8% 
increase compared with those identified using the HbA1C≥6.5% criterion, and 
2.35 times of those with a diabetes diagnosis in the problem list. Assuming 
claims to be the gold standard, the extended definition also had a higher 
sensitivity at 79.2% (versus 70.8% when HbA1c≥6.5% criterion was used alone 
and 33.6% when the criterion of diabetes on problem list was used alone). The 
specificity of the extended definition was 97.9%. CONCLUSIONS: This study 
explored the feasibility of identifying the diabetic patients in the Quintile EMR 
data and confirmed good concordance of the diabetes definition between EMRs 
and claims. When linked EMR and claims data are used, the diagnosis of diabetes 
is strengthened when patients have evidence of diabetes in both EMR and 
claims.  
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HOW DO PHARMACEUTICAL MARGINS VARY BY REGION, THERAPEUTIC AREA 
AND COUNTRY GROSS DOMESTIC PRODUCT?  
Donze B, Patel P 
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OBJECTIVES: Mapping the pharmaceutical distribution margin variations 
according to country wealth and therapy areas may provide insight into the 
developing trends of medicine supply across the globe. To confirm any trends, 
we compared pharmaceutical margins for diabetic, multiple sclerosis and 
oncology drugs in various countries to the country gross domestic product (GDP). 
METHODS: Using data from PRICENTRICTM, we collected ex-factory and public 
prices (excl. VAT) for various branded products from three therapy areas 
(diabetes, multiple sclerosis and oncology). Countries with unregulated 
distribution margins were excluded from the analysis. We calculated the average 
distribution margins between ex-factory price and public price across countries, 
regions and therapy areas. We also compared distribution margins to GDP per 
capita (International Monetary Fund 2012) to investigate trends between the two 
parameters. The analysis investigates two key areas: 1. Correlation between 
distribution margins across therapy areas and regions and 2: The relationship 
between pharmaceutical margins and GDP per capita across countries. RESULTS: 
In Asia-Pacific, we find that the distribution margins are higher for diabetic 
drugs (32%) than multiple sclerosis (23%) and oncology (16%). In Europe, a similar 
pattern follows: distribution margins in diabetes (28%), multiple sclerosis (12%) 
and oncology (12%). The margins in Middle-East-Africa and US however, remain 
constant across all three therapy areas. We found no correlation between the 
drug distribution margins and GDP aside from the Middle-East-African region, 
which showed a higher pharmaceutical margin in high GDP countries. 
CONCLUSIONS: Our analysis shows that pharmaceutical margins vary the most 
depending on region and therapy area with little correlation to the GDP per 
capita. Pharmaceutical distribution margins are higher in Asia-Pacific than in 
Middle-East-Africa, Europe and US.  
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USE OF COMMON DATA MODEL TO MEANINGFULLY COMPARE TREATMENT 
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OBJECTIVES: Use of a Common Data Model (CDM) to standardize data format 
and assumptions facilitates consistent and efficient application of research 
methods across disparate data sources, producing meaningfully comparable 
results. This study compared treatment patterns for patients diagnosed with 
depression in 2008-09 across multiple observational databases, after all source 
data was transformed into a CDM format. METHODS: Newly diagnosed 
depression patients were identified from 5 Administrative Claims and Electronic 
Health Record (EHR) databases, comprising ~300 million patients previously 
transformed into a CDM format. Patterns of initial treatment for anti-depressant 
drug classes (e.g. SSRI, SNRI, TCA, MAOI, Other) were analyzed using a common 
CDM analysis module. The Proportion of Days Covered (PDC) as well as patterns 
of continuation, discontinuation, augmentation, and switching was calculated 
for 365 days immediately following initial treatment. RESULTS: SSRIs were the 
most common first line treatment (72-75% across databases), followed by Other 
antidepressants (12-17%). The patterns of continuation varied by type of 
database: Government Claims (5%), Commercial Claims (14-15%), EHR (32%). 
Discontinuation was consistent across all Claims (65-69%) with EHR lower (46%). 
Switching rate (12-14%) and specific patterns of switching were consistent across 
all database types. Augmentation rate was consistent across all databases (7-8%); 
with the exception Government Claims (13%). The pattern of augmentation was 
variable depending on type of database. PDC was consistent across Claims (25-
28%) but varied from EHR (57%). On average across databases, TCAs had lowest 
PDC (25-28% Claims, 57% EHR) while SNRI’s had the highest (29-44% Claims, 53% 
EHR). Analysis was completed on all databases in less than two days. 
CONCLUSIONS: Common Data Models provide an efficient way of enabling 
meaningful comparisons across disparate data sources. Differences in results are 
likely due to differences in underlying populations, data capture process, and/or 
functional ability and/or incentive to record complete information in source 
data.  
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PREPARATION OF A HOSPITAL DATASET FOR ANALYSIS PRIOR TO A HOSPITAL 
AND HEALTH INSURER MERGER  
Jiandani S, Lovett A 
Mercer University, Atlanta, GA, USA  
OBJECTIVES: To provide a source document in the creation of a dataset for a 
hospital and health insurer merger. METHODS: A review of the literature was 
performed to determine best practices in the development of a dataset to link 
hospital data with health insurance data. Peer reviewed articles and reports were 
retrieved from the published literature from 2002 to 2012. RESULTS: Results 
revealed a total of 30 articles and reports. A summary of this information is 
provided as a step-by-step guide on how to setup a dataset. The purpose of data 
collection should be discussed in detail. The data must be de-identified due to 
HIPAA regulations. Patient data, such as date of birth, hospital admission, 
discharge date, sex, and ICD-9 code can be combined to form an identifier that is 
nearly 100% unique and found in both hospital and payer databases. This is 
stored as a separate dataset. Additionally, a dataset from the payer should be 
extracted and stored. The resulting datasets can then be sent to a Data 
Coordinating Center, where data is evaluated for quality assurance and 
combined into one master dataset. Prior to combining datasets it is helpful to 
identify potential research outcomes of interest to ensure that the variables are 
accurately represented by the data. CONCLUSIONS: Currently, there are few 
databases that allow researchers to follow a patient from hospital admission to 
post discharge. Researchers who obtain data offering a cross sectional view of a 
patient’s health status must find creative ways to link patients over time either 
making many assumptions or using various simulation methods. A hospital and 
health insurer merger offers a unique opportunity to develop a dataset to track 
patient outcomes.  
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